key: cord-0755229-o7hlfvrk
authors: Joshee, Shreeya; Vatti, Nikhil; Chang, Christopher
title: Long-Term Effects of COVID-19
date: 2022-01-12
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.12.017
sha: b7e88df91aed1835f910d5b3b071d61e08d0ee0e
doc_id: 755229
cord_uid: o7hlfvrk

COVID-19 is the third deadly coronavirus infection of the 21st century that has proven to be significantly more lethal than its predecessors, with the number of infected patients and deaths still increasing daily. From December 2019 to July 2021, this virus has infected nearly 200 million people and led to over 4 million deaths. Our understanding of COVID-19 is constantly progressing, giving better insight into the heterogeneous nature of its acute and long-term effects. Recent literature on the long-term health consequences of COVID-19 discusses the need for a comprehensive understanding of the multisystemic pathophysiology, clinical predictors, and epidemiology to develop and inform an evidence-based, multidisciplinary management approach. A PubMed search was completed using variations on the term post-acute COVID-19. Only peer-reviewed studies in English published by July 17, 2021 were considered for inclusion. All studies discussed in this text are from adult populations unless specified (as with MIS-C). The preliminary evidence on the pulmonary, cardiovascular, neurological, hematological, multisystem inflammatory, renal, endocrine, gastrointestinal, and integumentary sequelae of shows that COVID-19 continues after acute infection. Interdisciplinary monitoring with holistic management that considers nutrition, physical therapy, psychological management, meditation, and mindfulness in addition to medication will allow for the early detection of post-acute COVID-19 sequelae symptoms and prevent long-term systemic damage. This review serves as a guideline for effective management based on current evidence, but clinicians should modify recommendations to reflect each patient's unique needs and the most up-to-date evidence. The presence of long-term effects presents another reason for vaccination against COVID-19.

A comprehensive list of risk factors for the development of pulmonary manifestations for postacute COVID-19 can be found in Table 2 . In a study of 1733 patients from China, patients categorized as having a more severe hospital stay were more likely to have diffusion impairments (4.6 times) and report fatigue (2.69 times) than less severe counterparts (Supplemental Figure   1 ). 17 There is also an increased prevalence of fatigue and dyspnea in ICU patients than non-ICU groups four weeks after acute infection resolution. 47 6MWT are prognostic factors for illness severity as those with more severe disease had a higher proportion of subjects below the lower limit of the normal range (Supplemental Figure 1) . 17 Odds for developing pulmonary fibrosis were significantly increased in subjects with increased urea nitrogen (OR=7.149) and D-dimer levels (OR= 1.066) at admission. 48

Priority for prognostic screening for pulmonary sequelae of post-acute COVID-19 should be given to those who are symptomatic or show appropriate clinical predictors. Management recommendations for those that meet these criteria can be found in Table 2 . radiological resolution of pulmonary abnormalities occurs in ≥ 50% of patients within three weeks of discharge; therefore, imaging on non-symptomatic patients may be unnecessary. 96 Steroid use in the setting of post-acute COVID-19 has mixed results; therefore, steroid-sparing therapies should be considered when possible. 17 An observational study in the United Kingdom has shown some rapid functional improvements with corticosteroid therapy. 38 Out of the 837 patients assessed by telephone at four weeks post-infection resolution, 35 (4.8%) were initially diagnosed with interstitial lung disease and significant functional deficits. These 35 patients were brought in for outpatient evaluation where 30 were diagnosed with persistent interstitial lung changes and were offered steroid treatment with a maximum dose of 0.5 mg/kg oral prednisolone for three weeks. Improvements were noted in transfer factor (31.6% ± 27.6, P < 0.001) and forced vital capacity (9.6% ± 13.0, P = 0.014) with treatment, and significant symptomatic and radiological improvement.

Questions that remain include whether or not patients with significant lung involvement ever go back to pre-COVID-19 baseline, both symptomatically or by objective measures of lung function.

In addition, we also do not know how long it takes for symptoms to resolve completely or for lung function to fully recover. Future studies involving medications that can help decrease permanent lung damage such as pulmonary fibrosis would be beneficial. A breakdown of the major studies looking at post-acute COVID-19 cardiac effects can be found in Table 3 . Increases in cardiac troponins may indicate underlying cardiovascular pathology and is correlated with increased severity of acute illness and use of mechanical ventilation during hospitalization, cardiac dysfunction, arrhythmias, and death. 97 

The pathophysiology behind the cardiovascular sequalae of post-acute COVID-19 can be found in Figure 1 . These findings point to immune-mediated pathogenesis in the cardiovascular sequelae of post-acute COVID-19 instead of viral that leads to cardiac fibrosis. Imbalances in electrolytes can also interfere with electrical conduction in myocytes resulting in fatal rhythmic abnormalities. Hydroxychloroquine and azithromycin cause QT prolongation which can lead to torsade de pointes and fatal arrhythmias. 98 In patients at risk of cardiovascular symptoms of COVID-19, medication list and electrolyte levels should be closely monitored to reduce instances of arrhythmias.

History of increased troponin, disease severity, higher viral load and pneumonia increase the risk of cardiovascular sequelae in patients who have had COVID-19. Patients with elevated troponin levels are also at an increased risk due to higher white blood cell counts and longer prothrombin times. 97 cardiac fibrosis. 100 These lab markers may serve as prognostic indicators of post-COVID patients that may have cardiac sequelae due to fibrosis. Cardiac fibrosis is central to the pathophysiology of heart failure (HF) which explains increased incidence of Acute-HF in COVID-19 and acute decompensation in patients with Chronic-HF in this study of 3080 patients in Spain. 43 Prolonged corticosteroid use may increase viral shedding this increasing the odds of developing cardiovascular and other systemic sequelae. A multi-center randomized control trial of 86 patients with COVID-19 found that early use of corticosteroids (methylprednisolone) prolongs viral shedding in patients with COVID-19 pneumonia by suppressing immune cells. 101 In this single-blind prospective trial, patients were either given 1 mg/kg per day of methylprednisolone or 100 mL 0.9% normal saline for seven days within 72 hours of being admitted to the hospital. Viral RNA was detectable in the methylprednisolone group (11 days; interquartile range [IQR] 6-16 days), which was significantly longer than that in the control group (8 days IQR [2-12 days], p = 0.030) with throat cultures. CD3+ T-cells and CD8+ T-cells in the methylprednisolone group were also lower than the control group (p < 0.05). However, this study also found no significant differences in other secondary outcomes nor incidence of clinical deterioration.

Corticosteroid use was beneficial in reducing patient mortality in patients with ARDS (Hazard Ratio =0.38). 102 patients were assigned to either take dexamethasone 6mg once a day for ten days or usual care.

Reduction in mortality with glucocorticoid therapy varied greatly depending on the level of respiratory support at the time of randomization. Mortality was lower in treatment groups in patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio [RR] = 0.64) or oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; RR = 0.82) but not in subjects receiving no respiratory support (17.8% vs. 14.0%; RR = 1.19). 103 Though corticosteroids may cause systemic sequelae issues in the long term, it would not be reasonable to delay treatment given the mortality benefits in patients that need respiratory support or have ARDS.

Major concerns in the cardiovascular sequelae of COVID-19 are acute coronary syndrome, myocarditis, arrhythmias, cardiogenic shock, and medication-induced heart conditions. Full cardiac workup should be limited to patients with active symptoms or at increased risk. Point-ofcare EKG, transthoracic echocardiogram, laboratory tests for C-reactive protein (CRP) and

Troponin-T, and pro-inflammatory markers (TNF-alpha, CCL5, IL-6, IL-8, IL-18, and IFN- 

There are many unanswered questions on the long-term cardiovascular effects of COVID-19. This is an evolving question due to the novelty of COVID-19. We do not know if post-COVID arrhythmias are permanent or temporary. We do not know how long patients will need to avoid proarrhythmic drugs. We also do not know if post-COVID associated myocarditis or cardiomyopathy and related congestive heart failure will fully recover. The duration of treatment with angiotensin converting enzymes or beta blockers in these patients is also unknown. Another question is how long should limitations on strenuous activity remain. Future studies should focus on determining risk factors for long-term cardiovascular side effects and the development of mitigation measures to prevent these sequelae.

J o u r n a l P r e -p r o o f 

COVID-19 survivors report prolonged anosmia/ageusia, headaches, "brain fog"/memory loss, fatigue, malaise, and non-restorative sleep. 16, 17, 19, 47 . A breakdown of the major studies looking at post-acute COVID-19 neurological effects can be found in Table 3 . The prevalence of "brain fog" lacks significant scientific validity due to the lack of objective evidence.

A summary of the pathophysiology of neurological effects of post-acute COVID-19 can be found in Figure 1 .

The severity of illness, ICU admission, MIS-C, and certain medication during acute infection all increase risk of neurological sequelae in the post-acute COVID-19. A retrospective cohort study with 236,371 patients found substantial neurological and psychiatric morbidity among patients with severe illness. 53 ICU admissions are also associated with increased neuropsychiatric symptom manifestation (depression, anxiety, etc.) but not cognitive symptoms (memory loss and headache). Instances of neuropsychiatric diseases increase with encephalopathy during the acute phase of illness (Supplemental Figure 1) . 53 Case reports of children with MIS-C show unexpectedly high instances of neurological involvement (40%) as well. 107 Persistent anosmia after infection resolution may be a prognostic sign of a milder disease since it is prevalent in people with less severe COVID-19. It occurs due to Increased production of Immunoglobulin A J o u r n a l P r e -p r o o f limits viral spread in those with mild-COVID but escalates local inflammatory reactions in the olfactory system. 57

Medications used in acute-COVID-19 such as lopinavir-ritonavir and corticosteroids have neurological side effects that can manifest and persist during the acute or post-acute phase of illness. Ototoxicity mediated sensorineural hearing loss is associated with lopinavir-ritonavir treatment though this effect is rare and resolves around 20 weeks after discontinuation. 108 A multi-center cohort study in France unrelated to COVID-19 with 88 patients showed prednisone use >20mg/day caused delirium and manic mood changes in 52% of patients. 109 A controlled, open-label trial of 6,425 patients that looked at dexamethasone (6 mg once a day for ten days) as a potential treatment for patients hospitalized with COVID-19 had four adverse reactions, one of which included psychosis. 103 The neurological side-effects of corticosteroids are infrequent but can still cause significant neuropsychological and peripheral symptoms. Corticosteroids are frequently used in hospital and outpatient settings during acute COVID-19 infection, so clinicians must consider the neurological effects of these medications when monitoring patients in the outpatient setting.

There are no specific published guidelines on screening protocols for neurological disorders due to COVID-19 other than for postural orthostatic tachycardia syndrome (POTS). Primary care providers should use standard screening tools to evaluate for common disorders such as anxiety, depression, PTSD, and OCD. 54 Standard therapies should be implemented for all conditions with referral to neurological specialists for refractory conditions or imaging abnormalities. Diagnostic 

As in the case of pulmonary and cardiovascular manifestations, the duration of symptoms is still unknown. The effectiveness of rehabilitation exercises in recovering function is not clear. Post-COVID-19 depression must be distinguished from depression due to pandemic related secondary issues, including work, school and economic factors. Olfactory rehabilitation exercises have been shown to improve identification, discrimination and threshold for odor detection. 110 However, it is unclear how effective olfactory rehabilitation exercises are for people who have not spontaneously regained sense of smell after COVID-19 infection.

Epidemiology A breakdown of the major studies looking at post-acute COVID-19 hematological effects can be found in Table 3 . Common hematological findings of an acute-COVID infection are lymphocytopenia, neutrophilia, eosinopenia, and thrombocytopenia. 111 Thromboembolic events seen after infection resolution are immune-mediated rather than true thromboembolic events. 113 The increase in thrombotic risk due to SARS-CoV-2 is limited to acute illness even in those with severe disease that require admission. 59 Rashidi et al.'s multicenter prospective study of 1529 patients did not find a high rate of symptomatic VTE after hospital discharge. Of the 3.3% of patients who died after discharge, only 0.2% of those deaths could be attributed to VTE. Severely ill patients may have an increased risk for bleeding due to thrombocytopenia and depletion of coagulation factors, but it has been shown that thromboembolic events occur at higher rates than bleeding complications in the acute COVID-19. 88 Consequently, extended thromboprophylaxis after discharge may not provide any net benefit clinically, but randomized clinical trials are needed for additional verification. The acute illness severity and ICU admissions are risk factors for coagulation abnormality induced thromboembolisms. Severe disease is associated with an increased risk of VTE and arterial thromboembolic events, which increases short-term morbidity and mortality. 113, 114 ICU admission associated with increased pulmonary embolism as compared to non-ICU patients and independent factors include age, cancer, length of acute infection phase, low fibrinogen and higher D-dimer on admission, and D-dimer increment (DI) ≥1.5-fold. Fibrinogen, D-dimer, and DI predicted instances of VTE in the acute phase with a 93% sensitivity and 0.71% specificity. 58, 115 Patients with any of the mentioned clinical factors should be monitored for coagulation abnormalities that can present in any system and prioritized for post-illness follow-up when clinical indications are present.

Guidelines for management of thromboembolic conditions due to COVID-19 can be found on Table 2 . These are based on recommendations from American College of Cardiology and American Society of Hematology on care for patients in the hospital and in out-patient Posthospital thromboprophylaxis should also be given to at-risk patients and those that have undergone prolonged corticosteroid therapy, who do not have an active bleeding risk, to reduce risk of VTE. Extended use of thromboprophylaxis or use in all patients is not recommended at this time. 59

Unanswered questions include the mechanisms by which COVID-19 leads to long-term lipid abnormalities which can lead to atherogenesis. The role of statins in the maintenance of vascular health and integrity is unknown with regard to COVID-19.

Multi-inflammatory syndrome (MIS) sequelae are rare but severe complications following acute COVID-19 infection in previously symptomatic and asymptomatic individuals that present a few weeks after initial infection. 116 Though this syndrome was first documented in children <21 years old (MIS-C), there is an increasing number of case reports that show adults (21-50 years old) also may develop these sequelae (MIS-A). 117 The diagnostic criteria for MIS-C can be found in Table 2 . Similarities have been seen between MIS-C, Kawasaki Disease (KD) and Toxic Shock Syndrome (TSS) with common clinical features like persistent fever, systemic hyperinflammation, multiorgan involvement with prominent and severe GI symptoms, erythematous rashes, conjunctivitis, and inflammatory changes in the oral mucosa. 118 As a result, the pathophysiology of COVID-19 MIS-C may be revealed from studying these diseases. Critical differences between KD and MIS-C include ethnicities of those predominantly affected, organ systems attacked, and laboratory findings. 118 mild GI symptoms and lack of neurological and cardiovascular shock clinical characteristics. 118 MIS-C also shows increased D-dimer and troponin levels, lymphocytopenia, and thrombocytopenia. 119, 120 In contrast, TSS has nearly identical symptom presentation, laboratory findings, and drug response and only differs in ethnicity, affecting those of white descent more, and does not show increased troponin levels. 119, 120 .

Epidemiological information and subdivisions of the three distinct classes of MIS-C complied from Center from the Disease Control (CDC) database 4018 Reported Cases of MIS-C as of June 2, 2021 can be found in Figure 2 . 121,122 MIS-A still lacks clear criteria for diagnosis but has been described by the CDC using case reports from 16 patients between ages 21-50 years old. 123 This criteria includes Age ≥ 21, being hospitalized for ≥ 24 hours, Fever ≥ 38.0 °C or subjective fever for ≥ 24 hours OR within the first three days of hospitalization, meeting at least ONE primary clinical criteria (severe cardiac illness, rash AND non-purulent conjunctivitis), and may have secondary criteria (new-onset neurological symptoms, shock/hypotension that is not from medical therapy such as medications or dialysis, abdominal symptoms, thrombocytopenia). 124 They must also have laboratory evidence of SARS-COV-2 infection either by RT-PCR or serology and evidence of inflammation. 124 Little epidemiological data is currently available about MIS-A, and there are no registered Cochrane trials ongoing to study MIS-A specifically.

The pathophysiology behind the sequelae remains relatively unknown due to the small sample at increased thrombosis risk after COVID-19. 30 In addition, most patients with MIS symptoms are antibody positive but do not have an active viral infection. 30 Pediatric hospitalizations due to COVID-19 is on the rise again in unvaccinated children due to the increased transmission rates delta variant. 117 More data should be available soon and the mechanism MIS can be further explored.

MIS symptoms have been reported in both the pediatric (MIS-C) and adult (MIS-A) populations, but clinical predictors for MIS-C are currently more reliable due to their earlier characterization.

Clinical predictors for MIS-C can be found in Table 2 .

The American College of Rheumatology updated MIS-C diagnosis and treatment guidelines were released in December 2020 and are revised as more information becomes available. 30 Treatment guidelines for MIS-C can be found in Table 2 .

Little epidemiological data is currently available about MIS-A, and there are no registered Cochrane trials ongoing to study MIS-A specifically. Therefore, more case studies need to be gathered to develop an accurate epidemiological picture before analysing the pathophysiology J o u r n a l P r e -p r o o f 20 and management recommendation. For MIS-C, there is a greater database of cases, but this too needs to be expanded to further characterize pathophysiology and management recommendations.

Other rare long-term systemic effects of COVID 19 involve the renal, endocrine, integumentary, and GI systems. Pertinent information about the pathophysiology, clinical predictors, management recommendations can be found in Figure 1 and Table 2 respectively. A breakdown of the major studies looking at post-acute COVID-19 effects of these systems can be found in Table 3 CoV-2 and increased COVID-19 severity through modulation of host immune responses. 125, 126 How aggressive we should be in restoring gut microbiome post-COVID-19 is unclear and is a candidate for future studies.

Increased cases of urticaria have been reported after COVID-19. Urticaria is seen post many other viral infections. Is COVID-19 different in this regard or does it lead to longer duration of chronic urticaria, such as that seen in autoimmune or chronic idiopathic urticaria.

Patients with severe disease, increased risk factors, and symptomatic and/or hospitalized individuals should be prioritized for in-person or telemedicine visits (Supplemental Figure 2) .

Long-term management should focus on a holistic approach that involves physical therapy, nutrition, and psychological interventions in addition to medication-based methods.

Rehabilitation in the post-acute COVID-19 involves appropriate management of the consequences of ventilatory support, prolonged immobilization, and bed rest. These include impaired lung function, physical deconditioning that leads to impaired muscle function, and cognitive impairments. 127 Patients should resume regular activities 6-8 weeks post-discharge, but this may be more challenging in patients with severe disease, extended hospital stays, or cannot be conducted in patients with COVID-19, they should do low-/moderate-intensity exercise to reduce muscle deterioration and improve pulmonary function. 128 A randomized control trial of 150 participants showed an increased rate of 6MWT results in participants with critical illness who participated in outpatient physiotherapy (PT) after ICU discharge. 129 With all the challenges of the pandemic that patients may face, mental health becomes a significant concern. The physical effects of long-term COVID-19 sequelae can often be intertwined with the psychological outlook of patients and efforts should be made to ensure that mental health is preserved. To this end, complementary therapies such as acupuncture, massage, low-impact yoga, and Tai Chi may be of benefit.

The The clear association between COVID-19 and long lasting sequelae that has the potential to affect multiple organ systems is another reason why everyone should be vaccinated. No longer can any demographic be confident that their illness may be mild and that they will completely recover from it. The best way to prevent the acute illness and long-term effects of COVID-19 is not to get the infection in the first place. Social distancing measures, masking and vaccines are effective ways of lowering the risk of infection.

The work done on this manuscript was divided as follows: 

The third coronavirus epidemic in the third millennium: What's next?

Clinical Characteristics of Coronavirus Disease 2019 in China

Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward followup study

A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications

The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals

Broad Auto-Reactive IgM Responses Are Common In Critically Ill COVID-19 Patients

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human Olfactory Neuroepithelium and Brain. iScience

Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators

© 2022 Mayo Foundation for Medical Education and Research

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy

Kidney Biopsy Findings in Patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Newly diagnosed diabetes mellitus, DKA, and COVID-19: Causality or coincidence? A report of three cases

Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus

Subacute Thyroiditis from COVID-19 Infection: A Case Report and Review of Literature

Subacute thyroiditis associated with COVID-19

Thyrotoxicosis Following SARS-CoV-2 Infection

© 2022 Mayo Foundation for Medical Education and Research

Gastrointestinal sequelae 90 days after discharge for COVID-19

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Clinical conditions of patients with chronic urticaria during the pandemic caused by the 2019 Novel Coronavirus Disease (COVID-19)

Angioedema and COVID-19: A New Dermatological Manifestation?

Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature

Idiopathic nonhistaminergic acquired angioedema in a patient with coronavirus disease 2019

Lung transplantation for patients with severe COVID-19

Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology

Risk factors associated with disease severity and length of hospital stay in COVID-19 patients

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease

Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Dexamethasone in Hospitalized Patients with Covid-19

Recognition and Initial Management of Fulminant Myocarditis

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis

Corticosteroids for viral myocarditis

Multisystem Inflammatory Syndrome in Children in New York State

Ototoxicity May Be Associated with Protease Inhibitor Therapy

Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion

Effects of olfactory training: a meta-analysis

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China

The risk of thrombosis after acute-COVID-19 infection

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study

HAN Archive -00442 | Health Alert Network (HAN)

Laboratory Confirmed COVID-19 Associated Hospitalizations

COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome-the superantigen hypothesis

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City

Center for Disease Control and Prevention (CDC). Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States

COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States

Multisystem Inflammatory Syndrome in J

Alterations in Gut Microbiota of Patients With

During Time of Hospitalization

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Pan American Health Organization (PAHO). W. Rehabilitation Considerations during the COVID-19 Outbreak. www.paho.org/coronavirus

COVID-19: Interim Guidance on Rehabilitation in the Hospital and Post-Hospital Phase from a

Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months of follow-up

Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study

Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China

The authors would like to thank Rani Vatti, MD for her valuable suggestions and review of this paper.

 65 Kidney biopsies done at Columbia University 15 (88%) AKI, 9 (53%) nephrotic-range proteinuria, 5 (29%) collapsing glomerulopathy, 4 (24%) isolated acute tubular injury, 2 (12%) membranous glomerulopathy, 1 (6%) anti-GBM nephritis, 1 crescentic transformation of lupus nephritis, and 1 minimal change disease Case reports Oral angioedema with or without urticaria on the tongue and/or lips 1-2 weeks into the acute disease course